Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) just unveiled an update.
Alphamab Oncology announced a positive profit alert, expecting a profit of not less than RMB20.0 million for the first half of 2025, reversing a loss of approximately RMB44.9 million in the same period of 2024. This turnaround is attributed to milestone revenue from three licensed collaborations and sales revenue from a commercialized product, indicating a significant improvement in the company’s financial performance and market positioning.
More about Alphamab Oncology
Alphamab Oncology is a company incorporated in the Cayman Islands, focusing on the biotechnology industry. It specializes in developing and commercializing innovative biologics for cancer treatment, with an emphasis on licensed collaborations and commercialized products.
Average Trading Volume: 4,200,050
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.56B
For a thorough assessment of 9966 stock, go to TipRanks’ Stock Analysis page.